LAG3 (CD223) as a cancer immunotherapy target

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Cancer immunotherapies targeting CTLA4 and PD1-PDL1 have limitations, as many patients do not respond.
• The tumor microenvironment contains suppressive mechanisms and alternative inhibitory receptors (IRs) that can be targeted.
• Lymphocyte-activation gene-3 (LAG3) is the third IR being investigated for clinical cancer therapy.

Purpose of the Study:

• To explore the role of LAG3 as a target in cancer immunotherapy.
• To understand the mechanisms of LAG3-mediated immune suppression and its potential synergy with other IRs.
• To evaluate the clinical impact of LAG3-targeted therapies, particularly in combination with PD1 inhibitors.

Main Methods:

• Review of current literature on LAG3 function and targeted therapies.
• Analysis of preclinical and clinical data on LAG3 and PD1-PDL1 co-targeting.
• Investigation of LAG3's unique signaling pathways and its interplay with other immune checkpoints.

Main Results:

• LAG3 is upregulated in the tumor microenvironment, contributing to T cell exhaustion.
• LAG3 exhibits synergy with PD1, suggesting dual-targeting potential.
• Multiple LAG3-targeted therapies are in clinical and preclinical development.

Conclusions:

• LAG3 represents a promising target for overcoming resistance to current cancer immunotherapies.
• Dual blockade of LAG3 and PD1 may enhance anti-tumor responses.
• Clinical trial outcomes for LAG3-targeted therapies will significantly influence future cancer immunotherapy development.